Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis ; volume:11 ; number:1 ; day:20 ; month:11 ; year:2023 ; pages:97-112 ; date:2.2024
Rheumatology and therapy ; 11, Heft 1 (20.11.2023), 97-112, 2.2024
- Urheber
-
Rubbert-Roth, Andrea
Kakehasi, Adriana M.
Takeuchi, Tsutomu
Schmalzing, Marc
Palac, Hannah
Coombs, Derek
Liu, Jianzhong
Anyanwu, Samuel I.
Lippe, Ralph
Curtis, Jeffrey R.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-023-00621-6
- URN
-
urn:nbn:de:101:1-2024033110561620656586
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rubbert-Roth, Andrea
- Kakehasi, Adriana M.
- Takeuchi, Tsutomu
- Schmalzing, Marc
- Palac, Hannah
- Coombs, Derek
- Liu, Jianzhong
- Anyanwu, Samuel I.
- Lippe, Ralph
- Curtis, Jeffrey R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Complications of primary total hip arthroplasty among patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and primary osteoarthritis
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Frühe rheumatoide Arthritis: Upadacitinib-Monotherapie besser als Methotrexat
Upadacitinib (rheumatoide Arthritis) : Nutzenbewertung gemäß § 35a SGB V
Upadacitinib (rheumatoide Arthritis) : Nutzenbewertung gemäß § 35a SGB V
Upadacitinib (Psoriasis-Arthritis) : Addendum zum Auftrag A21-15
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Complications of primary total hip arthroplasty among patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and primary osteoarthritis
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Frühe rheumatoide Arthritis: Upadacitinib-Monotherapie besser als Methotrexat
Upadacitinib (rheumatoide Arthritis) : Nutzenbewertung gemäß § 35a SGB V
Upadacitinib (rheumatoide Arthritis) : Nutzenbewertung gemäß § 35a SGB V
Upadacitinib (Psoriasis-Arthritis) : Addendum zum Auftrag A21-15
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis
Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Complications of primary total hip arthroplasty among patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and primary osteoarthritis
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Frühe rheumatoide Arthritis: Upadacitinib-Monotherapie besser als Methotrexat
Upadacitinib (rheumatoide Arthritis) : Nutzenbewertung gemäß § 35a SGB V
Upadacitinib (rheumatoide Arthritis) : Nutzenbewertung gemäß § 35a SGB V